Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
Richemont Q1 Sales Beat Forecast as Cartier Demand Drives Strong Growth 
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom 
Stripe, Advent Offer $53 Billion Deal to Acquire PayPal: Reuters 
SEB Q2 Profit Rises on Strong Lending, Record Fee Income, Announces New Share Buyback 
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX 
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings 
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook 
Alibaba Stock Jumps as China Approves Apple Intelligence Powered by Qwen AI 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub 
UBS Starts CarTrade Tech With Buy Rating, Sees Strong Earnings Growth and ₹4,000 Target 
NEW YORK, Jan. 15, 2016 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Eastern District of Michigan on behalf of investors who purchased Esperion Therapeutics, Inc. (NASDAQ:ESPR) securities between August 18, 2015 and September 28, 2015.
Click here to learn about the case: http://docs.wongesq.com/ESPR-Info-Request-Form-1062. There is no cost or obligation to you.
The complaint alleges that Defendants issued false and misleading statements regarding the Company’s business and prospects, including that there was no clear path to approval for ETC-1002, the Company’s lead product candidate designed to lower LDL-cholesterol levels, and that the FDA had encouraged the Company to initiate a cardiovascular outcomes trial (“CVOT”) and that completion of a CVOT could be necessary prior to approval of ETC-1002.
On August 17, 2015, Esperion reported to investors material events from an August 2015 meeting with the FDA; the Company stated that during the meeting it was informed by the FDA that the Company would not have to complete a CVOT to gain approval of ETC-1002. Then in a September 28, 2015 news release the Company noted that the FDA had actually “encouraged the Company to initiate a cardiovascular outcomes trial promptly” and it may be necessary to have a completed CVOT prior to approval.
If you suffered a loss in Esperion Therapeutics you have until March 14, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://docs.wongesq.com/ESPR-Info-Request-Form-1062.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
